Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor
Crossref DOI link: https://doi.org/10.1007/s13300-019-0643-1
Published Online: 2019-06-18
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ishii, Hitoshi
Suzaki, Yuki
Miyata, Yuko
Matsui, Shingo http://orcid.org/0000-0002-6803-2135
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 15 March 2019
First Online: 18 June 2019